Attovia Therapeutics, Inc. (NASDAQ:ATTO) Stock Has Consensus Target Price of $42.20

Attovia Therapeutics, Inc. (NASDAQ:ATTO - Get Free Report) has received an average recommendation of "Moderate Buy" from the six brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $42.20.

Several analysts have issued reports on ATTO shares. Leerink Partners began coverage on Attovia Therapeutics in a research note on Monday, August 31st. They issued an "outperform" rating and a $52.00 price objective on the stock. Lifesci Capital began coverage on Attovia Therapeutics in a research note on Monday, August 31st. They issued an "outperform" rating and a $45.00 price target on the stock. Zacks Research raised Attovia Therapeutics to a "hold" rating in a report on Friday, September 4th. Citigroup assumed coverage on shares of Attovia Therapeutics in a research report on Monday, August 31st. They set a "buy" rating and a $30.00 price objective for the company. Finally, Wall Street Zen raised shares of Attovia Therapeutics to a "sell" rating in a research report on Saturday, September 19th.

Attovia Therapeutics Trading Up 5.3%

Shares of ATTO opened at $15.80 on Thursday. The company has a 50-day moving average price of $18.91. Attovia Therapeutics has a one year low of $12.94 and a one year high of $28.00. The company has a market cap of $721.27 million and a P/E ratio of -3.24.

Attovia Therapeutics (NASDAQ:ATTO - Get Free Report) last issued its earnings results on Wednesday, September 2nd. The company reported ($4.88) earnings per share (EPS) for the quarter. The firm had revenue of $0.45 million for the quarter. As a group, analysts expect that Attovia Therapeutics will post -4.06 earnings per share for the current year.

Insider Transactions at Attovia Therapeutics

In other Attovia Therapeutics news, major shareholder Global Strategic Fund I. Venbio acquired 382,352 shares of the business's stock in a transaction on Thursday, August 6th. The stock was purchased at an average price of $17.00 per share, with a total value of $6,499,984.00. Following the acquisition, the insider directly owned 4,181,367 shares of the company's stock, valued at approximately $71,083,239. This trade represents a 10.06% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Goldman Sachs Group Inc bought 500,000 shares of the firm's stock in a transaction on Thursday, August 6th. The shares were acquired at an average price of $17.00 per share, for a total transaction of $8,500,000.00. Following the transaction, the insider owned 3,020,632 shares in the company, valued at approximately $51,350,744. This represents a 19.84% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have purchased 2,740,587 shares of company stock worth $47,269,979.

About Attovia Therapeutics

Attovia Therapeutics, Inc NASDAQ: ATTO is a clinical-stage biopharmaceutical company focused on developing antibody-based medicines for immune-mediated and inflammatory diseases. The company is working to address conditions in which existing treatments may not provide adequate efficacy, durability, or convenience.

Attovia uses its proprietary antibody-engineering and drug-development capabilities to discover and advance biologic therapies designed to modulate disease-driving immune pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.